- Home
- ACIU vs HLXB Comparison
ACIU vs HLXB Comparison
Compare ACIU & HLXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- HLXB
- Stock Information
- Founded
- ACIU 2003
- HLXB 2021
- Country
- ACIU Switzerland
- HLXB United States
- Employees
- ACIU N/A
- HLXB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- HLXB
- Sector
- ACIU Health Care
- HLXB
- Exchange
- ACIU Nasdaq
- HLXB NYSE
- Market Cap
- ACIU 247.4M
- HLXB 253.2M
- IPO Year
- ACIU 2016
- HLXB 2024
- Fundamental
- Price
- ACIU $1.48
- HLXB $10.77
- Analyst Decision
- ACIU Strong Buy
- HLXB
- Analyst Count
- ACIU 2
- HLXB 0
- Target Price
- ACIU $12.00
- HLXB N/A
- AVG Volume (30 Days)
- ACIU 192.5K
- HLXB 25.7K
- Earning Date
- ACIU 05-12-2025
- HLXB 01-01-0001
- Dividend Yield
- ACIU N/A
- HLXB N/A
- EPS Growth
- ACIU N/A
- HLXB N/A
- EPS
- ACIU N/A
- HLXB 0.36
- Revenue
- ACIU $30,136,397.00
- HLXB N/A
- Revenue This Year
- ACIU N/A
- HLXB N/A
- Revenue Next Year
- ACIU $676.94
- HLXB N/A
- P/E Ratio
- ACIU N/A
- HLXB $30.15
- Revenue Growth
- ACIU 84.51
- HLXB N/A
- 52 Week Low
- ACIU $1.43
- HLXB $10.14
- 52 Week High
- ACIU $4.98
- HLXB $11.59
- Technical
- Relative Strength Index (RSI)
- ACIU 24.24
- HLXB N/A
- Support Level
- ACIU $1.48
- HLXB N/A
- Resistance Level
- ACIU $1.62
- HLXB N/A
- Average True Range (ATR)
- ACIU 0.12
- HLXB 0.00
- MACD
- ACIU -0.00
- HLXB 0.00
- Stochastic Oscillator
- ACIU 9.43
- HLXB 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.